Welcome to LookChem.com Sign In|Join Free

Article Doi

Improvement in oral bioavailability of 2,4-diaminopyrimidine c-Met inhibitors by incorporation of a 3-amidobenzazepin-2-one group

DOI: 10.1016/j.bmc.2011.09.006

Source and publish data:

Bioorganic and Medicinal Chemistry p. 6274 - 6284 (2011)

Update date:2022-07-30

Topics:

Authors:

Milkiewicz, Karen L.Milkiewicz, Karen L.

Aimone, Lisa D.Aimone, Lisa D.

Albom, Mark S.Albom, Mark S.

Angeles, Thelma S.Angeles, Thelma S.

Chang, HongChang, Hong

Grobelny, Jennifer V.Grobelny, Jennifer V.

Husten, JeanHusten, Jean

LoSardo, ChristineLoSardo, Christine

Miknyoczki, SheilaMiknyoczki, Sheila

Murthy, SeethaMurthy, Seetha

Rolon-Steele, DamarisRolon-Steele, Damaris

Underiner, Ted L.Underiner, Ted L.

Weinberg, Linda R.Weinberg, Linda R.

Worrell, Candace S.Worrell, Candace S.

Zeigler, Kelli S.Zeigler, Kelli S.

Dorsey, Bruce D.Dorsey, Bruce D.

Read Full Text PDF DownLoad Join now for total 90,000,000 free articles

Article abstract of DOI:10.1016/j.bmc.2011.09.006

The hepatocyte growth factor (HGF)-c-Met signaling axis is involved in the mediation of many biological activities, including angiogenesis, proliferation, cell survival, cell motility, and morphogenesis. Dysregulation of c-Met signaling (e.g., overexpress

View More

Full text of DOI:10.1016/j.bmc.2011.09.006

Products guided by the article

Product name:(R)-2-{5-chloro-2-[5,5-dimethyl-2-oxo-3-(2,2,2-trifluoroacetylamino)-2,3,4,5-tetrahydro-1H-1-benzazepin-8-ylamino]pyrimidin-4-ylamino}-3-fluoro-N-methylbenzamide

Cas No:1346168-84-0

1346168-84-0

R&D Labs maybe for 1346168-84-0

Relevant to this article

Hot Product